New EASO framework sets out how Europe can turn major advances in obesity medicines into better, more equitable care New EASO framework sets out how Europe can turn major advances in obesity medicines into better, more equitable care Policy, Position Statements
Semaglutide: 4-Year Weight Loss and Cardiovascular Benefits Semaglutide: 4-Year Weight Loss and Cardiovascular Benefits ECO
Watch – Birgitta van der Kolk discuss winning the EASO – NN Foundation Award for Basic Science Watch – Birgitta van der Kolk discuss winning the EASO – NN Foundation Award for Basic Science ECO
English English 
French
